Skip to content

Cryoablation for Advanced and Refractory Desmoid Tumors

Cryoablation for Advanced and Refractory Desmoid Tumors

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06113094
Acronym
CARDT
Enrollment
30
Registered
2023-11-02
Start date
2020-07-07
Completion date
2023-12-31
Last updated
2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Desmoid Tumors

Keywords

Desmoid tumors, Fibromatosis, Invasive tumors, Radiotherapy, Cryoablation

Brief summary

Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population. The watch and wait policy is the standard of care for newly diagnosed patients in Europe. Patients who progress have first-line medical treatment, surgery is no longer the treatment because there is a high rate of recurrence (\> 60%) and radiotherapy is not very suitable because the patients are often young and the tumors are large. Cryoablation seems to be an effective therapeutic option that should be evaluated.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (≥18 years old) * Having undergone cryoablation for an advanced desmoid tumor refractory to medical treatment * Having not expressed their opposition, after being informed, to the reuse of their data for the purposes of this research.

Exclusion criteria

* Subject who expressed their opposition to participating in the study * Patient already included in another ongoing study * Subject under guardianship or curatorship * Subject under safeguard of justice

Design outcomes

Primary

MeasureTime frame
Progression-free survival assessed using RECIST(Response evaluation criteria in solid tumors) criteriaat 6 months after cryoablation

Countries

France

Contacts

Primary ContactPierre AULOGE, MD
pierre.auloge@chru-strasbourg.fr33 3 69 55 15 26

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026